-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
China's first novel coronavirus mRNA vaccine will be put into production next month
The new crown mRNA pneumonia vaccine by the Academy of Military Medicine Chinese Academy of Military Sciences, love Bo Biological Technology Co.
Recently, China's first new coronavirus mRNA vaccine production workshop was completed and put into production in Yuxi, Yunnan
The total investment in the new base is expected to be 520 million yuan
mRNA is a natural molecule that provides instructions to human cells, stimulates the body's immunity to produce antigens, and fights corresponding diseases
The mRNA gene encoding the S protein is directly injected into the human body, and the human cell is used to synthesize the S protein in the human body to stimulate the body to produce antibodies
In layman's terms, this is equivalent to handing over a detailed virus file to the body's immune system
The mRNA vaccine is currently the vaccine with the highest protection rate (95%) among the results of phase III clinical trials announced globally
At the same time, its R&D technology threshold is relatively high
There are several reasons for China's comprehensive promotion of mRNA vaccines:
1.
The selection of vaccine antigen targets used in China is more precise, and the induced neutralizing antibodies have higher specificity
2.
China's mRNA vaccine core raw materials and equipment have been produced locally, which means that once production approval is obtained, production capacity will be able to achieve rapid expansion to meet supply
3.
The mRNA produced in China uses a single pre-filled injection format that can be stored at room temperature for a week or at 4°C for a long time
At present, in addition to the smooth progress in the research and development of mRNA vaccines, China's recombinant vaccines based on traditional technologies are already at the forefront of the world
According to statistics, up to now, 5 vaccine projects in China have entered phase III clinical trials, and vaccination has been initiated in more than 10 countries, and no serious adverse reactions have been reported
.
(Source: Internet, for reference only)
